We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,364 hedge funds and large institutions have $81.1B invested in Bristol-Myers Squibb in 2023 Q4 according to their latest regulatory filings, with 253 funds opening new positions, 672 increasing their positions, 1,209 reducing their positions, and 240 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $1.7B | Put options by funds: $1.2B

2.47% more ownership

Funds ownership: 75.18%77.65% (+2.5%)

5% more first-time investments, than exits

New positions opened: 253 | Existing positions closed: 240

1% less funds holding

Funds holding: 2,3882,364 (-24)

11% less capital invested

Capital invested by funds: $91.2B → $81.1B (-$10.2B)

43% less funds holding in top 10

Funds holding in top 10: 4224 (-18)

44% less repeat investments, than reductions

Existing positions increased: 672 | Existing positions reduced: 1,209

Holders
2,364
Holders Change
-24
Holders Change %
-1.01%
% of All Funds
34.46%
Holding in Top 10
24
Holding in Top 10 Change
-18
Holding in Top 10 Change %
-42.86%
% of All Funds
0.35%
New
253
Increased
672
Reduced
1,209
Closed
240
Calls
$1.7B
Puts
$1.2B
Net Calls
+$498M
Net Calls Change
-$7.96M
Name Holding Trade Value Shares
Change
Change in
Stake
TAM
1026
Trust Asset Management
Texas
$1.26M
EHWM
1027
Eads & Heald Wealth Management
Georgia
$1.25M -$123K -2,346 -9%
First Manhattan
1028
First Manhattan
New York
$1.24M -$334K -6,359 -21%
PFC
1029
Poplar Forest Capital
California
$1.23M
AI
1030
Atom Investors
Texas
$1.23M +$1.26M +23,921 New
CAM
1031
Cobblestone Asset Management
Virginia
$1.22M +$611K +11,644 +95%
CIA
1032
Concurrent Investment Advisors
Florida
$1.22M +$1.25M +23,863 New
MME
1033
Meag Munich Ergo
Germany
$1.22M
AWM
1034
Aries Wealth Management
Maine
$1.22M -$107K -2,037 -8%
HI
1035
Harbour Investments
Wisconsin
$1.22M -$129K -2,452 -9%
Luther King Capital Management (LKCM)
1036
Luther King Capital Management (LKCM)
Texas
$1.22M -$342K -6,522 -21%
HI
1037
Horizon Investments
North Carolina
$1.22M -$1.47M -27,927 -54%
QIM
1038
Quantitative Investment Management
Virginia
$1.21M +$1.24M +23,614 New
RCAG
1039
Rehmann Capital Advisory Group
Michigan
$1.21M +$2.42K +46 +0.2%
WPC
1040
White Pine Capital
Minnesota
$1.2M -$332K -6,322 -21%
HCM
1041
Highlander Capital Management
New Jersey
$1.2M +$60.9K +1,160 +5%
HW
1042
Hancock Whitney
Mississippi
$1.19M -$209K -3,990 -15%
RMCM
1043
Reynders McVeigh Capital Management
Massachusetts
$1.19M -$107K -2,039 -8%
TFS
1044
Thoroughbred Financial Services
Tennessee
$1.19M +$55.9K +1,065 +5%
DPIM
1045
Duff & Phelps Investment Management
Illinois
$1.18M
KA
1046
Kovack Advisors
Florida
$1.18M +$277K +5,279 +30%
SC
1047
Schulhoff & Co
Ohio
$1.18M
DJSG
1048
D.J. St. Germain
Massachusetts
$1.18M +$8.82K +168 +0.7%
CCA
1049
Cobblestone Capital Advisors
New York
$1.18M +$210K +3,997 +21%
HH
1050
Hilltop Holdings
Texas
$1.17M -$527K -10,037 -31%

BMY Hedge Fund Activity: Q4 2023 in Review

2,364 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2023, worth a combined $81.1B — down 11% from $91.2B a quarter earlier.

Buyers outnumbered sellers: 253 funds opened new BMY positions and 240 closed out — a net gain of 13 holders — while 672 added to existing stakes and 1,209 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.16B. The largest seller was Capital International Investors, cutting an estimated $414M.

  • 2,364 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2023, down from 2,388 in Q3 2023.
  • Funds reported $81.1B of Bristol-Myers Squibb stock for Q4 2023, down 11% quarter-over-quarter.
  • 253 funds opened new Bristol-Myers Squibb positions in Q4 2023 and 240 closed out, a net change of +13 holders.
  • The largest Bristol-Myers Squibb buyer in Q4 2023 was Morgan Stanley, an estimated $1.16B added.
  • The largest Bristol-Myers Squibb seller in Q4 2023 was Capital International Investors, an estimated $414M sold.

Based on aggregated 13F filings for Q4 2023.